Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Liabilities and Shareholders Equity (2020 - 2025)

Historic Liabilities and Shareholders Equity for Cytek Biosciences (CTKB) over the last 6 years, with Q3 2025 value amounting to $494.9 million.

  • Cytek Biosciences' Liabilities and Shareholders Equity rose 75.18% to $494.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 billion, marking a year-over-year increase of 45.17%. This contributed to the annual value of $499.5 million for FY2024, which is 101.99% up from last year.
  • Cytek Biosciences' Liabilities and Shareholders Equity amounted to $494.9 million in Q3 2025, which was up 75.18% from $493.3 million recorded in Q2 2025.
  • Over the past 5 years, Cytek Biosciences' Liabilities and Shareholders Equity peaked at $525.1 million during Q2 2023, and registered a low of $230.3 million during Q2 2021.
  • Its 5-year average for Liabilities and Shareholders Equity is $480.3 million, with a median of $493.1 million in 2022.
  • As far as peak fluctuations go, Cytek Biosciences' Liabilities and Shareholders Equity surged by 11400.87% in 2022, and later plummeted by 787.14% in 2024.
  • Over the past 5 years, Cytek Biosciences' Liabilities and Shareholders Equity (Quarter) stood at $463.3 million in 2021, then grew by 12.12% to $519.5 million in 2022, then decreased by 4.82% to $494.5 million in 2023, then rose by 1.02% to $499.5 million in 2024, then decreased by 0.92% to $494.9 million in 2025.
  • Its last three reported values are $494.9 million in Q3 2025, $493.3 million for Q2 2025, and $482.6 million during Q1 2025.